HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The company is headquartered in New York City, New York and currently employs 82 full-time employees. The company went IPO on 2019-04-18. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers. The firm has partnered with Gilead Sciences, Inc. to develop therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1.
Follow-Up Questions
¿Quién es el CEO de HOOKIPA Pharma Inc?
Dr. Malte Peters es el Chief Executive Officer de HOOKIPA Pharma Inc, se unió a la empresa desde 2023.
¿Qué tal es el rendimiento del precio de la acción HOOK?
El precio actual de HOOK es de $0.877, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de HOOKIPA Pharma Inc?
HOOKIPA Pharma Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de HOOKIPA Pharma Inc?
La capitalización bursátil actual de HOOKIPA Pharma Inc es $10.8M
¿Es HOOKIPA Pharma Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 4 analistas han realizado calificaciones de análisis para HOOKIPA Pharma Inc, incluyendo 0 fuerte compra, 0 compra, 3 mantener, 1 venta, y 0 fuerte venta
